In vivo gene editing has been achieved in a phase I clinical trial and results in a strong reduction of the level of a pathogenic protein. While preliminary, these results open the way for many applications in gene therapy.
Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial